Cogenics to Serve as Astellas' Global Genotyping Provider | GenomeWeb
NEW YORK (GenomeWeb News) – Clinical Data’s Cogenics division will provide genotyping services to Tokyo-based drug developer Astellas Pharma, the company said today.
 
Under the agreement, Cogenics will serve as Astellas’ exclusive global provider of biorepository and extraction services and whole-genome association and targeted genotyping services for clinical studies in the US, Europe, and Asia.
 
Cogenics has facilities in North Carolina, Texas, the UK, France, and Germany.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.